Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
UNKNOWN
NCT02929303

Expanded Access of Omegaven IV Fat Emulsion to Infants and Children With PNALD

Sponsor: Wake Forest University Health Sciences

View on ClinicalTrials.gov

Summary

This is an expanded access protocol for use of intravenous fish oil infusion, Omegaven, in infants and children with parenteral nutrition associated liver disease (PNALD) to decrease elevated liver enzymes and direct bilirubin. This study aims to describe the response of PNALD after use of Omegaven by normalization of serum levels of liver enzymes and bilirubin.

Official title: Expanded Access of Omegaven IV Fat Emulsion (Fish Oil Infusion) to Infants and Children With Parenteral Nutrition-associated Liver Disease

Key Details

Gender

All

Age Range

Any - 17 Years

Study Type

EXPANDED_ACCESS

Enrollment

Not specified

Start Date

Not specified

Completion Date

Not specified

Last Updated

2026-09-28

Healthy Volunteers

Not specified

Interventions

DRUG

Omegaven IV lipid emulsion

Therapy is started at a dose of 1 gm/kg/day over 12 hrs. Omegaven may be infused via a central or peripheral IV. If additional fat calories are needed they will be provided by the enteral route.

Locations (1)

Advocate Children's Hospital

Park Ridge, Illinois, United States